Development of 7SK snRNA Mimics That Inhibit HIV Transcription

The significance of small noncoding RNAs in the pathogenesis of cardiovascular diseases

With the advancement of high-throughput sequencing and bioinformatics, an increasing number of overlooked small noncoding RNAs (sncRNAs) have emerged. These sncRNAs predominantly comprise transfer RNA-derived fragments (tsRNAs), PIWI-interacting RNAs (piRNAs), Ro-associated non-coding RNAs (RNYs or Y-RNAs), small nucleolar RNAs (snoRNAs), and small nuclear RNAs (snRNAs). Each of these RNA types possesses distinct biological properties and plays specific roles in both physiological and pathological processes. The differential expression of sncRNAs substantially affects the occurrence and progression of various systemic diseases. However, their roles in the cardiovascular system remain unclear. Therefore, understanding the functionality and mechanisms of sncRNAs in the cardiovascular system holds promise for identifying novel targets and strategies for the diagnosis, prevention, and treatment of cardiovascular diseases. This review examines the biological characteristics of sncRNAs and their potential roles in cardiovascular diseases.

Chronic sleep deprivation promotes experimental autoimmune uveitis through STAT1 phosphorylation, ISG15 expression and enhanced pathogenicity of macrophages

Chronic sleep deprivation (CSD) is increasingly common in modern society and is linked to various diseases, including autoimmune conditions like experimental autoimmune uveitis (EAU), a severe ocular inflammation. The pathogenesis of EAU remains unclear, but poor sleep quality has been shown to exacerbate inflammation through immune modulation. To explore this relationship, we conducted a clinical study at the Ophthalmology Center of Renmin Hospital of Wuhan University (July 2023-July 2024), assessing sleep quality in uveitis patients using the Pittsburgh Sleep Quality Index (PSQI). Based on PSQI scores, patients were categorized into four groups, and their symptoms and characteristics were recorded. Simultaneously, a B10.RIII mouse model of CSD and EAU was developed. Western blotting assessed the phosphorylation of Signal Transducer and Activator of Transcription 1 (STAT1) and the expression of Interferon-Stimulated Gene 15 (ISG15) expression, while immunofluorescence and western blotting evaluated macrophage activity and cytokine secretion. Clinical results showed a strong correlation between poor sleep quality and worsened inflammatory symptoms. In mice, CSD increased STAT1 phosphorylation and ISG15 expression, enhancing macrophage activity and worsening ocular inflammation. Our findings suggest that CSD exacerbates EAU through STAT1 phosphorylation, ISG15 expression, and macrophage activation. The clinical data further support this mechanism, indicating that improving sleep quality could reduce the risk of autoimmune diseases and offering new insights into the connection between sleep and immune function.

Interventions during Early Infection: Opening a Window for an HIV Cure?

Although combination antiretroviral therapy (ART) has been a landmark achievement for the treatment of human immunodeficiency virus (HIV), an HIV cure has remained elusive. Elimination of latent HIV reservoirs that persist throughout HIV infection is the most challenging barrier to an HIV cure. The progressive HIV infection is marked by the increasing size and diversity of latent HIV reservoirs until an effective immune response is mobilized, which can control but not eliminate HIV infection. The stalemate between HIV replication and the immune response is manifested by the establishment of a viral set point. ART initiation during the early stage limits HIV reservoir development, preserves immune function, improves the quality of life, and may lead to ART-free viral remission in a few people living with HIV (PLWH). However, for the overwhelming majority of PLWH, early ART initiation alone does not cure HIV, and lifelong ART is needed to sustain viral suppression. A critical area of research is focused on determining whether HIV could be functionally cured if additional treatments are provided alongside early ART. Several HIV interventions including Block and Lock, Shock and Kill, broadly neutralizing antibody (bNAb) therapy, adoptive CD8+ T cell therapy, and gene therapy have demonstrated delayed viral rebound and/or viral remission in animal models and/or some PLWH. Whether or not their application during early infection can improve the success of HIV remission is less studied. Herein, we review the current state of clinical and investigative HIV interventions and discuss their potential to improve the likelihood of post-treatment remission if initiated during early infection.